DER PRADIKTIVE WERT DER TUMORMARKERKOMBINATION CA-125 UND BETA-2-MIKROGLOBULIN BEI OVARIALKARZINOM

Translated title of the contribution: The follow-up of ovarian cancer patients with beta-2-microglobulin and CA-125

Z. Hernádi, V. Molnar, B. Juhasz, R. Polka, B. Margitai

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Beta-2-microglobulin (b2m) and or CA-125 levels were measured in 367 serum samples of 66 ovarian cancer patients. CA-125 was found to be a suitable tool, even in single use, to monitorise the clinical course of the disease with acceptable sensitivity (o. 89) and specificity (o. 94). B2m showed a sensitivity of the same level (o. 87) the specificity of it however proved to be low (o. 48). In consequence of its low specificity the b2m as a single marker is not applicable in ovarian cancer. However, the addition of b2m to CA-125 resulted in higher specificity and sensitivity, as b2m probably has a different spectrum and yielded correct results at that points of the follow-up where CA-125 produced pseudo-positive or pseudo-negative results. The combination of b2m and CA-125 tumormarkers seems to be a suitable tool for follow-up ovarian cancer patients under and after treatment.

Original languageGerman
Pages (from-to)6-9
Number of pages4
JournalZentralblatt fur Gynakologie
Volume114
Issue number1
Publication statusPublished - 1992

Fingerprint

beta 2-Microglobulin
Ovarian Neoplasms
Sensitivity and Specificity
Serum

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

DER PRADIKTIVE WERT DER TUMORMARKERKOMBINATION CA-125 UND BETA-2-MIKROGLOBULIN BEI OVARIALKARZINOM. / Hernádi, Z.; Molnar, V.; Juhasz, B.; Polka, R.; Margitai, B.

In: Zentralblatt fur Gynakologie, Vol. 114, No. 1, 1992, p. 6-9.

Research output: Contribution to journalArticle

Hernádi, Z. ; Molnar, V. ; Juhasz, B. ; Polka, R. ; Margitai, B. / DER PRADIKTIVE WERT DER TUMORMARKERKOMBINATION CA-125 UND BETA-2-MIKROGLOBULIN BEI OVARIALKARZINOM. In: Zentralblatt fur Gynakologie. 1992 ; Vol. 114, No. 1. pp. 6-9.
@article{febc3d3ffc654c808be6a0af1dc4bdca,
title = "DER PRADIKTIVE WERT DER TUMORMARKERKOMBINATION CA-125 UND BETA-2-MIKROGLOBULIN BEI OVARIALKARZINOM",
abstract = "Beta-2-microglobulin (b2m) and or CA-125 levels were measured in 367 serum samples of 66 ovarian cancer patients. CA-125 was found to be a suitable tool, even in single use, to monitorise the clinical course of the disease with acceptable sensitivity (o. 89) and specificity (o. 94). B2m showed a sensitivity of the same level (o. 87) the specificity of it however proved to be low (o. 48). In consequence of its low specificity the b2m as a single marker is not applicable in ovarian cancer. However, the addition of b2m to CA-125 resulted in higher specificity and sensitivity, as b2m probably has a different spectrum and yielded correct results at that points of the follow-up where CA-125 produced pseudo-positive or pseudo-negative results. The combination of b2m and CA-125 tumormarkers seems to be a suitable tool for follow-up ovarian cancer patients under and after treatment.",
author = "Z. Hern{\'a}di and V. Molnar and B. Juhasz and R. Polka and B. Margitai",
year = "1992",
language = "German",
volume = "114",
pages = "6--9",
journal = "Aktuelle Dermatologie",
issn = "0340-2541",
publisher = "Georg Thieme Verlag",
number = "1",

}

TY - JOUR

T1 - DER PRADIKTIVE WERT DER TUMORMARKERKOMBINATION CA-125 UND BETA-2-MIKROGLOBULIN BEI OVARIALKARZINOM

AU - Hernádi, Z.

AU - Molnar, V.

AU - Juhasz, B.

AU - Polka, R.

AU - Margitai, B.

PY - 1992

Y1 - 1992

N2 - Beta-2-microglobulin (b2m) and or CA-125 levels were measured in 367 serum samples of 66 ovarian cancer patients. CA-125 was found to be a suitable tool, even in single use, to monitorise the clinical course of the disease with acceptable sensitivity (o. 89) and specificity (o. 94). B2m showed a sensitivity of the same level (o. 87) the specificity of it however proved to be low (o. 48). In consequence of its low specificity the b2m as a single marker is not applicable in ovarian cancer. However, the addition of b2m to CA-125 resulted in higher specificity and sensitivity, as b2m probably has a different spectrum and yielded correct results at that points of the follow-up where CA-125 produced pseudo-positive or pseudo-negative results. The combination of b2m and CA-125 tumormarkers seems to be a suitable tool for follow-up ovarian cancer patients under and after treatment.

AB - Beta-2-microglobulin (b2m) and or CA-125 levels were measured in 367 serum samples of 66 ovarian cancer patients. CA-125 was found to be a suitable tool, even in single use, to monitorise the clinical course of the disease with acceptable sensitivity (o. 89) and specificity (o. 94). B2m showed a sensitivity of the same level (o. 87) the specificity of it however proved to be low (o. 48). In consequence of its low specificity the b2m as a single marker is not applicable in ovarian cancer. However, the addition of b2m to CA-125 resulted in higher specificity and sensitivity, as b2m probably has a different spectrum and yielded correct results at that points of the follow-up where CA-125 produced pseudo-positive or pseudo-negative results. The combination of b2m and CA-125 tumormarkers seems to be a suitable tool for follow-up ovarian cancer patients under and after treatment.

UR - http://www.scopus.com/inward/record.url?scp=0026563454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026563454&partnerID=8YFLogxK

M3 - Article

C2 - 1585745

AN - SCOPUS:0026563454

VL - 114

SP - 6

EP - 9

JO - Aktuelle Dermatologie

JF - Aktuelle Dermatologie

SN - 0340-2541

IS - 1

ER -